SUBCUTANEOUS NADH IMPLANT IN THE MANAGEMENT OF CHRONIC FATIGUE SYNDROME: AN INTEGRATIVE REVIEW OF CLINICAL AND METABOLIC EVIDENCE
DOI:
https://doi.org/10.56238/levv16n54-040Keywords:
NADH, Chronic Fatigue Syndrome, Subcutaneous Administration, Energy Metabolism, SupplementationAbstract
This integrative review aimed to gather, analyze, and synthesize the available clinical, metabolic, and pharmacological evidence on the use of NADH in the management of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), with emphasis on evaluating the therapeutic potential of the subcutaneous route as an alternative to oral administration. The methodology followed the model proposed by Whittemore and Knafl (2005), complemented by the guidelines of Mendes, Silveira, and Galvão (2008), encompassing six structured stages. In total, 31 scientific studies were selected from recognized databases such as PubMed, ScienceDirect, Scopus, and SpringerLink. Inclusion criteria comprised clinical, experimental, and review studies addressing interventions with NADH, its precursors (such as NMN and nicotinamide riboside), energy metabolism, and alternative routes of administration. Evidence indicates that NADH exerts positive effects on cellular energy levels, fatigue symptoms, and quality of life in individuals with ME/CFS, especially through oral supplementation. However, the low bioavailability of this route has stimulated interest in alternative delivery forms. Recent pharmacokinetic studies, including experiments with nanoencapsulation, enzymatic regeneration, and injectable systems, support the theoretical feasibility of subcutaneous NADH administration, although specific clinical trials confirming its efficacy are still lacking. It is concluded that the subcutaneous route represents a promising and rational alternative to enhance the therapeutic effects of NADH in ME/CFS patients, mainly due to its greater stability, continuous absorption, and systemic availability. Controlled clinical trials are needed to confirm the safety, applicability, and efficacy of this route.
Downloads
References
CASTRO-MARRERO, J. et al. Effect of dietary coenzyme Q10 plus NADH supplementation on fatigue perception and health-related quality of life in individuals with myalgic encephalomyelitis/chronic fatigue syndrome. Nutrients, v. 13, n. 8, p. 2658, 2021. DOI: https://doi.org/10.3390/nu13082658
CALVO, C. F. et al. Does oral coenzyme Q10 plus NADH supplementation improve fatigue and biochemical parameters in CFS? Academia.edu, 2015.
DEHHAGHI, M. et al. The role of kynurenine pathway and NAD+ metabolism in myalgic encephalomyelitis/chronic fatigue syndrome. Aging and Disease, v. 13, n. 1, p. 257-276, 2022. DOI: https://doi.org/10.14336/AD.2021.0824
KAVYANI, S. et al. Could the kynurenine pathway be the key missing piece of myalgic encephalomyelitis/chronic fatigue syndrome complex puzzle? Cellular and Molecular Life Sciences, v. 79, n. 6, p. 1-17, 2022. DOI: https://doi.org/10.1007/s00018-022-04380-5
NAVARRO, D. C. et al. NAD+ metabolism in the immune response, autoimmunity and inflammageing. British Journal of Pharmacology, v. 178, n. 8, p. 1721-1736, 2021.
HOEL, F. et al. A map of metabolic phenotypes in patients with myalgic encephalomyelitis/chronic fatigue syndrome. JCI Insight, v. 6, n. 3, p. e149217, 2021. DOI: https://doi.org/10.1172/jci.insight.149217
GERMAIN, A. et al. Metabolic profiling of a myalgic encephalomyelitis/chronic fatigue syndrome discovery cohort reveals disturbances in fatty acid and lipid metabolism. Molecular BioSystems, v. 13, n. 2, p. 371-379, 2017. DOI: https://doi.org/10.1039/C6MB00600K
MAYA, J. Surveying the metabolic and dysfunctional profiles of T cells and NK cells in myalgic encephalomyelitis/chronic fatigue syndrome. International Journal of Molecular Sciences, v. 24, n. 3, p. 2793, 2023. DOI: https://doi.org/10.3390/ijms241511937
XUE, M. et al. A combination of nicotinamide and D-ribose (RiaGev) is safe and effective to increase NAD+ metabolome in healthy middle-aged adults. Nutrients, v. 14, n. 11, p. 2247, 2022. DOI: https://doi.org/10.3390/nu14112219
DEWI, D. et al. Efficacy of nicotinamide mononucleotide supplementation (NMN) in blood NAD for anti-aging in adults: A systematic review. Journal of Advanced Research in Medical and Health Science, v. 10, n. 1, p. 78-86, 2024.
CHEN, L. et al. Metalla-aromatic oligomers: efficient photocatalytic activation for phototherapy. Journal of Medicinal Chemistry, v. 68, n. 1, p. 89-101, 2025. DOI: https://doi.org/10.1021/acs.jmedchem.5c00690
MA, H. et al. AIE polymersome nanozyme mimics NADH oxidase for photocatalytic tumor suppression. Journal of the American Chemical Society, v. 147, n. 5, p. 1983–1995, 2025. DOI: https://doi.org/10.1021/jacs.5c06533
GRUSZCZYŃSKA, J. et al. Biochemical clocks in fingerprints: energy transfer between free tryptophan and NADH. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, v. 312, p. 123456, 2025. DOI: https://doi.org/10.1016/j.saa.2025.127057
MISHRA, S. et al. Graphene for CO₂ conversion and NADH regeneration. Inorganic Chemistry Communications, v. 155, p. 111234, 2025.
LU, Y.; ZHOU, W. Photoenzymatic catalytic cascade for NADH regeneration. Catalysis Letters, v. 155, p. 245–252, 2025. DOI: https://doi.org/10.1007/s10562-025-05208-0
PAN, J.; LUO, H. Coenzyme I and Chronic Fatigue Syndrome. In: Biology of Nicotinamide Coenzymes: From Basic Research to Clinical Applications. Springer, 2025. DOI: https://doi.org/10.1007/978-981-97-9877-3_31
MENDES, K. D. S.; SILVEIRA, R. C. D. C.; GALVÃO, C. M. Revisão integrativa: método de pesquisa para a incorporação de evidências na saúde e na enfermagem. Texto & Contexto Enfermagem, v. 17, n. 4, p. 758–764, 2008. DOI: https://doi.org/10.1590/S0104-07072008000400018
WHITTEMORE, R.; KNAFL, K. The integrative review: updated methodology. Journal of Advanced Nursing, v. 52, n. 5, p. 546–553, 2005. DOI: https://doi.org/10.1111/j.1365-2648.2005.03621.x
